Poseida Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PSTX research report →
Range $10 – $15
Price Chart
About the company
Poseida Therapeutics, Inc. , a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies.
- CEO
- Mark J. Gergen
- IPO
- 2020
- Employees
- 350
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on PSTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $925.93M
- P/E
- -6.93
- Fwd P/E
- 41.30
- PEG
- -0.08
- P/S
- 14.31
- P/B
- 8.26
- EV/EBITDA
- -8.87
- Div Yield
- 0.00%
- Gross Margin
- -142.29%
- Op Margin
- -200.15%
- Net Margin
- -190.76%
- ROE
- -84.75%
- ROIC
- -62.11%
Latest fiscal year · YoY change
- Revenue
- $64.70M-50.4%
- Gross Profit
- $-92,069,000-173.5%
- Op Income
- $-129,504,000
- Net Income
- $-123,430,000-92.9%
- EPS
- $-1.37-53.9%
- OCF Growth
- -244.3%
- FCF Growth
- -210.2%
- 52W High
- $9.67
- 52W Low
- $1.87
- 50D MA
- $6.66
- 200D MA
- $3.82
- Beta
- 0.54
- RSI (14)
- 75
- Avg Volume
- 1.80M
No earnings-call transcripts are available for PSTX yet.
- Free Float
- 66.4%
- Shares Outstanding
- 97.47M
- Float Shares
- 64.70M
of shares held by institutions
99 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 4.91M | ▼ 44.91K |
| Boxer Capital, LLC | 2.00M | ▼ 2.48M |
| Nuveen Asset Management, LLC | 299.30K | ▼ 5.31K |
| Cigogne Management SA | 120.00K | ▲ 120.00K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 8, 25 | Malin Life Sciences Holdings Ltd | other | 11,835,673 |
| Jan 8, 25 | Amado Rafael | sell | 55,200 |
| Jan 8, 25 | Amado Rafael | sell | 27,350 |
| Jan 8, 25 | Amado Rafael | other | 58,950 |
| Jan 8, 25 | Corning Luke | sell | 27,350 |
| Jan 8, 25 | Corning Luke | sell | 28,500 |
| Jan 8, 25 | Corning Luke | sell | 27,350 |
| Jan 8, 25 | Corning Luke | sell | 45,833 |
| Jan 8, 25 | Corning Luke | other | 58,950 |
| Jan 8, 25 | Schmid John P. | sell | 32,076 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PSTX coverage
Recent articles, reports, and earnings notes.
No research on PSTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PSTX report →Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
globenewswire.com · Jul 23
Roche set to finalise $1.5bn Poseida Therapeutics takeover
proactiveinvestors.com · Jan 8
Roche to complete acquisition of U.S. biopharma company Poseida
reuters.com · Jan 8
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders
businesswire.com · Dec 20
Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run?
zacks.com · Dec 13
Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting
prnewswire.com · Dec 9
Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross?
zacks.com · Nov 28
POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX
businesswire.com · Nov 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.